DEV Community

Cover image for DoseTrace, PartsProof and CivicBinder
Compound Labs
Compound Labs

Posted on Originally published at thecompound.tech

DoseTrace, PartsProof and CivicBinder

This issue carries short descriptions of Compound Labs products that turn FDA, EU, and federal accessibility requirements into binders, reports, and runbooks. Each section names who uses the product and what they receive.

What this issue carries

These products turn requirements into documents people can review, sign, file, or hand to a vendor.


DoseTrace

DoseTrace

DoseTrace, screenshot of the landing page DoseTrace prepares a DSCSA readiness binder for independent pharmacies. Pharmacy owners get a dated exemption determination, trading-partner verification log, three SOPs, a tracing response runbook, training attestations, and a six-year retention plan. You pay $99 once after a fifteen-minute intake.

dosetrace.thecompound.tech


PartsProof

PartsProof

PartsProof, screenshot of the landing page PartsProof prepares Cyber Resilience Act reporting documentation for small hardware and software makers selling into the EU. You receive a scope memo, disclosure policy, security.txt, vulnerability-handling SOP, CycloneDX SBOM, and 24-hour, 72-hour, and 14-day reporting runbook. The Readiness Pack costs $79 once.

partsproof.thecompound.tech


CivicBinder

CivicBinder

CivicBinder, screenshot of the landing page CivicBinder prepares small public entities for the federal ADA Title II deadline. Cities, counties, districts, and housing authorities receive a website audit, complete PDF inventory, Accessibility Policy, public statement, and dated remediation plan in one binder. The Readiness Binder costs $299, or $499 for school districts and entities serving 50,000 or more.

civicbinder.org


Multiple shipped products, taken apart, few times a week. What each one does, what it cost to build, what the pipeline behind it looks like, and what the numbers did, read off the repository and the live site, not written from memory. Join the list.

Top comments (0)